News Search Results
Jan 30, 2026, 11:00 ET Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jan 30, 2026, 02:56 ET Aquaporin announces withdrawal of its offering and resolves to initiate insolvency proceedings
company with operations in Denmark (HQ), Singapore, Turkey, the United States, and China. We are committed to rethinking water filtration with biotechnology to solve global water challenges. By combining three disciplines from the world of natural sciences: biology, chemistry, and physics, we have created
More news about: Aquaporin A/S
Jan 30, 2026, 02:54 ET Aquaporin announces withdrawal of its offering and resolves to initiate insolvency proceedings
company with operations in Denmark (HQ), Singapore, Turkey, the United States, and China. We are committed to rethinking water filtration with biotechnology to solve global water challenges. By combining three disciplines from the world of natural sciences: biology, chemistry, and physics, we have created
More news about: Aquaporin A/S
Jan 29, 2026, 17:31 ET Chronic Hepatitis D Market Poised for Significant Growth During the Forecast Period (2025-2034) as Emerging Therapies Drive Optimism | DelveInsight
Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences,
More news about: DelveInsight Business Research, LLP
Jan 29, 2026, 16:50 ET Libris Innovations Welcomes Ramani Varanasi as Chief Executive Officer
Innovations' efforts to advance and support new ventures originating from IBRI and partner innovation, while providing advisory counsel to help early-stage biotechnology companies attract the capital and talent needed to succeed. Her appointment reflects IBRI's continued focus on strengthening the pathway from translational
More news about: Indiana Biosciences Research Institute
Jan 29, 2026, 16:46 ET Myosin Therapeutics Invited to Present at Biocom California's Global Partnering & Investor Conference
during the conference may request a meeting via the event's partnering system.About Myosin TherapeuticsMyosin Therapeutics is a biotechnology company based in Jupiter, Florida, developing first-in-class therapies for oncology and CNS disorders by targeting molecular nanomotor proteins.
More news about: Myosin Therapeutics Inc.
Jan 29, 2026, 16:05 ET BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
Notes may be made only by means of an offering memorandum.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Jan 29, 2026, 13:31 ET Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
for networking on islet transplantation and beta cell replacement, making Avant's participation particularly significant for the emerging biotechnology company.Dr. Brandtner is assessing promising cells for inclusion with Avant's Cell-in-a-Box® technology, developed in partnership
More news about: USA News Group
Jan 29, 2026, 11:15 ET PranaX Corporation Closes $17 million Oversubscribed Series A Round
Corporation, a leading biotechnology company focused on regenerative biologics, today announced the closing of its oversubscribed $17 million Series A financing. The Series A round was led by family offices, trusts, and individual investors, a group with deep expertise across biotechnology, regenerative medicine,
More news about: PranaX
Jan 29, 2026, 11:05 ET Slope and LabConnect Expand Partnership Momentum with Multiple API-Integrated Clinical Trials Launched in Q4 2025
slopeclinical.com.About LabConnectLabConnect is redefining central laboratory services as a technology-driven partner for pharmaceutical and biotechnology companies. Our decentralized network model provides sponsors with access to the industry's most comprehensive global testing menu,
More news about: Slope
Jan 29, 2026, 09:10 ET Concerto Biosciences Signs Development and Commercialization Agreement with Sacco System to Advance Next-Generation Microbial Ingredient Discovery
Biosciences®, the microbial ecology company, today announced that it has signed a development and commercialization agreement with Sacco System, a global biotechnology company specializing in the research, development and production of natural and innovative biotechnological solutions for the food, nutraceutical,
More news about: Concerto Biosciences
Jan 29, 2026, 09:00 ET bitBiome and Tojo Vikas Announce Strategic Collaboration in Sustainable Flavor & Fragrance Biomanufacturing
market knowledge, customer relationships, and long-standing expertise in ingredient commercialization, combined with bitBiome's differentiated biotechnology platform for discovering and producing novel synthetic biological solutions including enzymes, proteins, strains and ingredients.bitBiome
More news about: bitBiome
Jan 29, 2026, 09:00 ET Up to 31.3% Body Weight Loss, Insilico Medicine Nominates AI-Powered GIPR Antagonist ISM0676 as Preclinical Candidate, Showing Synergistic Efficacy in Combination Therapy
management, with a total deal value approaching USD $120 million.About Insilico MedicineInsilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life
More news about: Insilico Medicine
Jan 29, 2026, 08:07 ET Former FDA Economist Dr. Nikki Tavasoli Joins Ocean Tomo, a Part of J.S. Held
bans—expertise directly applicable to antitrust, intellectual property disputes, and damages quantification in healthcare, pharmaceuticals, and biotechnology.Dr. Tavasoli's Research FocusDr. Tavasoli's research blends behavioral economics, health policy, and advanced data science,
More news about: J.S. Held
Jan 29, 2026, 08:01 ET GenScript Biotech Global Forum, "Scripting Possibilities", Convened AI and Biopharma Leaders in San Francisco
"The conversations throughout the day reinforced that biotechnology is indeed at an inflection point, but they also sharpened what that means in practice," said Ray Chen, PhD, President of GenScript Life Science
More news about: GenScript Biotech Corp.
Jan 29, 2026, 08:00 ET NanoMosaic Secures FDA Advanced Manufacturing Technology (AMT) Designation for Advanced Gene Therapy Analytics
the technology's advanced capabilities to other viral and non-viral modalities".About NanoMosaicNanoMosaic is a pioneering biotechnology company that develops innovative tools and technologies for multiomic biomarker detection and analysis. The company's flagship product, the NanoMosaic
More news about: NanoMosaic
Jan 29, 2026, 07:00 ET NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences
Corporate PresentationAbout NewcelX Ltd.NewcelX Ltd. (NASDAQ: NCEL) is a clinical-stage biotechnology company focused primarily on developing cell-based therapies for Type 1 Diabetes, supported by a broader platform spanning neurodegenerative and
More news about: NewcelX Ltd.
Jan 29, 2026, 06:58 ET Innovative Molecules Announces Completion of Phase 1 Program and Advancement to Phase 2 for Oral Adibelivir
foundation for transition into the next stage of clinical development."About Innovative MoleculesInnovative Molecules GmbH is a biotechnology company based in Munich, Germany, focused on developing transformative therapies for herpes infections. Its pipeline is dedicated to advancing novel
More news about: Innovative Molecules GmbH
Jan 29, 2026, 06:54 ET Innovative Molecules Announces Completion of Phase 1 Program and Advancement to Phase 2 for Oral Adibelivir
foundation for transition into the next stage of clinical development."About Innovative MoleculesInnovative Molecules GmbH is a biotechnology company based in Munich, Germany, focused on developing transformative therapies for herpes infections. Its pipeline is dedicated to advancing novel
More news about: Innovative Molecules GmbH
Jan 29, 2026, 06:30 ET Repertoire® Immune Medicines Announces Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases
CAMBRIDGE, Mass., Jan. 29, 2026 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a strategic
More news about: Repertoire Immune Medicines
Jan 29, 2026, 06:10 ET Sports Nutrition Market Size Expected to Reach USD 108.1 Billion by 2035, Growing at a CAGR of 7.55% | Research by Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Jan 29, 2026, 06:00 ET Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
(Nasdaq: SGMT) for exclusive rights in Greater China.About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Jan 29, 2026, 04:00 ET LifeArc Ventures 2025: New geographies and investments, a growing team and continued portfolio progress
transformative year for our portfolio companies and for our fund." LifeArc Ventures invests broadly across therapeutics and tech-enabled biotechnology companies across all modalities and therapeutic areas as part of its direct investment strategy. LifeArc Ventures also runs a fund of funds strategy
More news about: LifeArc
Jan 29, 2026, 03:30 ET TECregen Appoints Drug Development Veteran Dr. Klaas P. Zuideveld as Chief Executive Officer to Lead Thymus Regeneration Platform into Clinical Development
expansionBASEL, Switzerland, Jan. 29, 2026 /PRNewswire/ -- TECregen, a biotechnology company pioneering thymus rejuvenation, today announced the appointment of Dr. Klaas P. Zuideveld, Ph.D.,
More news about: TECregen AG
Jan 28, 2026, 20:00 ET Nona Biosciences Co-founds Innovative Alliance for Translational Medicine in Immunological Diseases, Advancing a New IIT-Driven Ecosystem
About Nona BiosciencesNona Biosciences is a global biotechnology company committed to cutting-edge technology innovations and providing integrated solutions from discovery to early clinical development and Investigator-Initiated
More news about: Nona Biosciences